Last reviewed · How we verify
CD19 or CD19-BCMA CAR-T
At a glance
| Generic name | CD19 or CD19-BCMA CAR-T |
|---|---|
| Sponsor | Nanjing Bioheng Biotech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis (PHASE1)
- A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. (PHASE1, PHASE2)
- Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases (EARLY_PHASE1)
- A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus (PHASE1)
- Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study (EARLY_PHASE1)
- A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia (EARLY_PHASE1)
- An Open-label Study of AZD0120 in Adults With Multiple Sclerosis (PHASE1)
- Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD19 or CD19-BCMA CAR-T CI brief — competitive landscape report
- CD19 or CD19-BCMA CAR-T updates RSS · CI watch RSS
- Nanjing Bioheng Biotech Co., Ltd. portfolio CI